$USPH
U S PHYSICAL THERAPY INC /NV

2020 Q2 Form 10-Q Financial Statement

#000114036120017773 Filed on August 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $83.86M $126.4M
YoY Change -33.64% 9.8%
Cost Of Revenue $64.50M $94.90M
YoY Change -32.03% 7.96%
Gross Profit $19.28M $31.43M
YoY Change -38.63% 15.73%
Gross Profit Margin 23.0% 24.87%
Selling, General & Admin $9.022M $11.53M
YoY Change -21.73% 13.81%
% of Gross Profit 46.78% 36.68%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.720M $2.560M
YoY Change 6.25% 6.67%
% of Gross Profit 14.1% 8.15%
Operating Expenses $9.022M $11.53M
YoY Change -21.73% 13.81%
Operating Profit $10.26M $19.90M
YoY Change -48.43% 16.87%
Interest Expense $400.0K $607.0K
YoY Change -34.1% 11.38%
% of Operating Profit 3.9% 3.05%
Other Income/Expense, Net $8.383M $5.220M
YoY Change 60.59%
Pretax Income $18.65M $25.12M
YoY Change -25.77% 52.2%
Income Tax $3.882M $5.318M
% Of Pretax Income 20.82% 21.17%
Net Earnings $10.23M $14.62M
YoY Change -30.01% 58.12%
Net Earnings / Revenue 12.2% 11.57%
Basic Earnings Per Share $0.99
Diluted Earnings Per Share $0.99 $1.141M
COMMON SHARES
Basic Shares Outstanding 12.84M
Diluted Shares Outstanding 12.84M

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.60M $34.90M
YoY Change 24.93% 28.78%
Cash & Equivalents $43.56M $34.86M
Short-Term Investments
Other Short-Term Assets $2.600M $7.102M
YoY Change -63.39% 36.58%
Inventory
Prepaid Expenses
Receivables $46.00M $44.92M
Other Receivables $0.00 $0.00
Total Short-Term Assets $92.10M $107.0M
YoY Change -13.93% 23.85%
LONG-TERM ASSETS
Property, Plant & Equipment $105.5M $20.02M
YoY Change 426.92% 1.63%
Goodwill $330.9M $303.5M
YoY Change 9.01%
Intangibles $54.90M $50.06M
YoY Change 9.67%
Long-Term Investments
YoY Change
Other Assets $1.600M $1.445M
YoY Change 10.73% 3.21%
Total Long-Term Assets $492.9M $453.8M
YoY Change 8.61% 28.17%
TOTAL ASSETS
Total Short-Term Assets $92.10M $107.0M
Total Long-Term Assets $492.9M $453.8M
Total Assets $585.0M $560.8M
YoY Change 4.31% 27.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $2.400M
YoY Change -25.0% 41.18%
Accrued Expenses $51.33M $31.35M
YoY Change 63.74% -11.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.635M $690.0K
YoY Change 571.74% -85.63%
Total Short-Term Liabilities $87.40M $57.02M
YoY Change 53.28% 36.09%
LONG-TERM LIABILITIES
Long-Term Debt $33.69M $66.32M
YoY Change -49.21% 17.17%
Other Long-Term Liabilities $61.60M $566.0K
YoY Change 10783.39% -79.04%
Total Long-Term Liabilities $33.69M $66.88M
YoY Change -49.64% 12.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $87.40M $57.02M
Total Long-Term Liabilities $33.69M $66.88M
Total Liabilities $329.8M $192.9M
YoY Change 70.97% -15.73%
SHAREHOLDERS EQUITY
Retained Earnings $176.6M
YoY Change
Common Stock $149.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M
YoY Change
Treasury Stock Shares $2.215M
Shareholders Equity $255.3M $229.3M
YoY Change
Total Liabilities & Shareholders Equity $585.0M $557.0M
YoY Change 5.03% 26.45%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $10.23M $14.62M
YoY Change -30.01% 58.12%
Depreciation, Depletion And Amortization $2.720M $2.560M
YoY Change 6.25% 6.67%
Cash From Operating Activities $31.98M $15.06M
YoY Change 112.35% -0.2%
INVESTING ACTIVITIES
Capital Expenditures -$1.880M -$2.380M
YoY Change -21.01% 27.27%
Acquisitions $30.60M
YoY Change 86.94%
Other Investing Activities -$280.0K -$18.24M
YoY Change -98.46% 118.44%
Cash From Investing Activities -$2.160M -$20.61M
YoY Change -89.52% 101.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -75.82M 20.17M
YoY Change -475.9% 716.6%
NET CHANGE
Cash From Operating Activities 31.98M 15.06M
Cash From Investing Activities -2.160M -20.61M
Cash From Financing Activities -75.82M 20.17M
Net Change In Cash -46.00M 14.62M
YoY Change -414.64% 99.18%
FREE CASH FLOW
Cash From Operating Activities $31.98M $15.06M
Capital Expenditures -$1.880M -$2.380M
Free Cash Flow $33.86M $17.44M
YoY Change 94.15% 2.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000885978
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
196574000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
242604000
CY2020Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
43429000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2446000
CY2020Q2 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1535000
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
2061000
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
3339000
CY2020Q2 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
2996000
dei Entity Registrant Name
EntityRegistrantName
U S PHYSICAL THERAPY INC /NV
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4958000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2100000
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
0
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
2200000
CY2020Q2 usph Relief Funds
ReliefFunds
7959000
CY2019Q2 usph Relief Funds
ReliefFunds
0
usph Relief Funds
ReliefFunds
7959000
usph Relief Funds
ReliefFunds
0
CY2020Q2 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
1073000
CY2019Q2 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
5823000
us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
1073000
us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
5823000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
4628000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
18239000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8880000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
345000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-701000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
4876000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
11633000
usph Payments To Acquire Redeemable Non Controlling Interest
PaymentsToAcquireRedeemableNonControllingInterest
2388000
usph Payments To Acquire Redeemable Non Controlling Interest
PaymentsToAcquireRedeemableNonControllingInterest
2053000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4478000
us-gaap Share Based Compensation
ShareBasedCompensation
3389000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
21000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
2468000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2759000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3560000
us-gaap Share Based Compensation
ShareBasedCompensation
3558000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-283000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-5969000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5421000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4956000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1737000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2446000
us-gaap Profit Loss
ProfitLoss
32175000
usph Gain On Sale Of Partnership Interest Net Of Tax
GainOnSaleOfPartnershipInterestNetOfTax
1073000
usph Gain On Sale Of Partnership Interest Net Of Tax
GainOnSaleOfPartnershipInterestNetOfTax
5514000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
48356000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5333000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23368000
us-gaap Interest Paid Net
InterestPaidNet
902000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43555000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34859000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7000
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
5707000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10270000
usph Purchase Of Business Seller Financing Portion
PurchaseOfBusinessSellerFinancingPortion
300000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8111000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
57000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4339000
us-gaap Interest Paid Net
InterestPaidNet
944000
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
7934000
usph Purchase Of Business Seller Financing Portion
PurchaseOfBusinessSellerFinancingPortion
4000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
99000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
80000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
112000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
56000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1057000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
314000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20007000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11491000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23548000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
674000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
112433000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
136936000
CY2020Q2 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
20311000
CY2019Q2 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
23026000
usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
43220000
usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
45070000
CY2020Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
739000
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
94000
CY2019Q2 us-gaap Restructuring Charges
RestructuringCharges
13000
us-gaap Restructuring Charges
RestructuringCharges
1987000
us-gaap Restructuring Charges
RestructuringCharges
9000
CY2020Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
64573000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
94948000
us-gaap Costs And Expenses
CostsAndExpenses
161599000
us-gaap Costs And Expenses
CostsAndExpenses
184461000
CY2020Q2 us-gaap Gross Profit
GrossProfit
19284000
CY2019Q2 us-gaap Gross Profit
GrossProfit
31425000
us-gaap Gross Profit
GrossProfit
34975000
us-gaap Gross Profit
GrossProfit
58143000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9022000
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11527000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20699000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22820000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
10262000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
19898000
us-gaap Operating Income Loss
OperatingIncomeLoss
14276000
us-gaap Operating Income Loss
OperatingIncomeLoss
35323000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83857000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126373000
CY2019Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
70669000
CY2019Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1240000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2100000
CY2019Q2 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1802000
us-gaap Profit Loss
ProfitLoss
32175000
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4531000
us-gaap Interest And Other Income
InterestAndOtherIncome
47000
us-gaap Interest And Other Income
InterestAndOtherIncome
20000
CY2020Q2 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
653000
CY2019Q2 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
607000
usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
1080000
usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
965000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8383000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5220000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7999000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4878000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18645000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
25118000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
22275000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
40201000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3882000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5318000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
14763000
CY2019Q2 us-gaap Profit Loss
ProfitLoss
19800000
us-gaap Profit Loss
ProfitLoss
18101000
CY2020Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
4000
CY2019Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
4000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4174000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8026000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
6853000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
14620000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10232000
us-gaap Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates
ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
0
CY2019Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.27
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.54
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-429000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.99
us-gaap Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates
ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
19000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18079000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
4110000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
28621000
CY2019Q2 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
3378000
usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
4792000
usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
5773000
CY2019Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
5180000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
9112000
us-gaap Net Income Loss
NetIncomeLoss
11248000
us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
144000
us-gaap Net Income Loss
NetIncomeLoss
23063000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.24
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12843000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12767000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12820000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12738000
CY2020Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.32
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
6891000
us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
138000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
21000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
65000
usph Medicare Accelerated And Advance Payment Funds
MedicareAcceleratedAndAdvancePaymentFunds
12861000
usph Medicare Accelerated And Advance Payment Funds
MedicareAcceleratedAndAdvancePaymentFunds
0
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
0
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
502000
CY2020Q2 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterest
137000
CY2019Q2 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterest
0
CY2020Q2 usph Notes Payable Due To Purchase Of Redeemable Non Controlling Interest
NotesPayableDueToPurchaseOfRedeemableNonControllingInterest
699000
CY2019Q2 usph Notes Payable Due To Purchase Of Redeemable Non Controlling Interest
NotesPayableDueToPurchaseOfRedeemableNonControllingInterest
0
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
11601000
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
386000
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
2780000
us-gaap Profit Loss
ProfitLoss
18101000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25241000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
242304000
CY2020Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1313000
CY2020Q2 us-gaap Stockholders Equity Other
StockholdersEquityOther
-38000
CY2020Q2 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1535000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
2771000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1502000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
256688000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
241701000
usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
4036000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3389000
usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
486000
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
4110000
us-gaap Stockholders Equity Other
StockholdersEquityOther
-81000
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
2061000
us-gaap Net Income Loss
NetIncomeLoss
11248000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
256688000
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
221173000
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2019Q2 us-gaap Stockholders Equity Other
StockholdersEquityOther
0
CY2019Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1717000
CY2019Q2 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1802000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
14620000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
230747000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
216875000
usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
636000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
104000
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6891000
usph Purchase Of Partnership Interests Redeemable Non Controlling Interests
PurchaseOfPartnershipInterestsRedeemableNonControllingInterests
298000
us-gaap Stockholders Equity Other
StockholdersEquityOther
-6000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
3339000
CY2020Q2 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax Shares
RevaluationOfRedeemableNonControllingInterestNetOfTaxShares
0
CY2020Q2 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
2466000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10232000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
2043000
CY2019Q2 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-3813000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-7250000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3558000
us-gaap Net Income Loss
NetIncomeLoss
23063000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
230747000
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div> <div><br/></div> <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, goodwill impairment, tradenames, allocations of purchase price, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.</div>
CY2019 usph Number Of Partnership In Which Interest Acquired
NumberOfPartnershipInWhichInterestAcquired
4
CY2019 usph Sale Of Noncontrolling Interest Percentage In Partnership One
SaleOfNoncontrollingInterestPercentageInPartnershipOne
0.01
CY2019 usph Tax Effect On Sale Of Noncontrolling Interest
TaxEffectOnSaleOfNoncontrollingInterest
196000
CY2019Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
3446000
CY2019Q2 usph Purchase Of Partnership Interests Redeemable Non Controlling Interests
PurchaseOfPartnershipInterestsRedeemableNonControllingInterests
298000
CY2020Q2 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
39
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
usph Percentage Of General Partnership Interest Owned
PercentageOfGeneralPartnershipInterestOwned
0.01
usph Number Of Third Party Facilities
NumberOfThirdPartyFacilities
29
CY2020Q1 usph Percentage Of Employees Furloughed Or Terminated
PercentageOfEmployeesFurloughedOrTerminated
0.40
CY2020Q1 dei Entity Number Of Employees
EntityNumberOfEmployees
5500
CY2020Q2 usph Number Of Furloughed Employees Returned
NumberOfFurloughedEmployeesReturned
750
usph Percentage Of Business Operational
PercentageOfBusinessOperational
0.90
CY2020Q2 usph Deferment Depositing Of Employer Share Social Security Taxes
DefermentDepositingOfEmployerShareSocialSecurityTaxes
2200000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1830000
CY2019Q2 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
0
CY2019Q2 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
0
CY2020Q2 usph Number Of Closed Clinics Sold
NumberOfClosedClinicsSold
11
usph Aggregate Sale Price Of Cinics
AggregateSalePriceOfCinics
1100000
CY2020Q2 usph Cash Received Related To Sale Of Clinics
CashReceivedRelatedToSaleOfClinics
700000
CY2020Q2 usph Note Receivable Related To Sale Of Clinics
NoteReceivableRelatedToSaleOfClinics
400000
usph Number Of Installments For Note Receivable In Sale Consideration
NumberOfInstallmentsForNoteReceivableInSaleConsideration
2
CY2020Q2 usph Number Of Clinics Operated
NumberOfClinicsOperated
554
CY2020Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
usph Number Of Operating Segments For Goodwill
NumberOfOperatingSegmentsForGoodwill
1
CY2019 usph Number Of Regions
NumberOfRegions
6
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1900000
CY2020Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
38320000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
51089000
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
4635000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
728000
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33685000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
50361000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4635000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
33642000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
38320000
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Reduction In Combined Physical Therapy Speech Language Pathology Expenses
ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses
3000
usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1
usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.50
usph Percentage Of Payment For Outpatient Therapy Services
PercentageOfPaymentForOutpatientTherapyServices
0.85
usph Net Revenue From Medicare
NetRevenueFromMedicare
44400000
usph Net Revenue From Medicare
NetRevenueFromMedicare
59400000
usph Difference Between Net Revenues And Corresponding Cash Collections Reflected Percentage Of Net Revenues
DifferenceBetweenNetRevenuesAndCorrespondingCashCollectionsReflectedPercentageOfNetRevenues
0.01
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83857000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126373000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
196574000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
242604000
usph Estimated Percentage Of Decrease In Payment
EstimatedPercentageOfDecreaseInPayment
0.09
usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
usph Reduction In Medicare Spending Percentage
ReductionInMedicareSpendingPercentage
0.02
CY2013Q2 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2015Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2018Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
usph Percentage Of Payment Adjustment Temporary Suspended
PercentageOfPaymentAdjustmentTemporarySuspended
0.02
usph Difference Between Actual Aggregate Contractual Reserve Percentages As Compared To Estimated Contractual Allowance Reserve Percentage
DifferenceBetweenActualAggregateContractualReservePercentagesAsComparedToEstimatedContractualAllowanceReservePercentage
0.01
usph Maximum Contractual Allowance Reserve Estimate
MaximumContractualAllowanceReserveEstimate
0.01
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
1232000
CY2020Q2 usph Gain On Sale Of Closed Clinics
GainOnSaleOfClosedClinics
1100000
CY2020Q2 usph Number Of Clinics Closed
NumberOfClinicsClosed
11
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10232000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
14620000
us-gaap Net Income Loss
NetIncomeLoss
11248000
us-gaap Net Income Loss
NetIncomeLoss
23063000
CY2020Q2 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
3344000
CY2019Q2 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-5169000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
5473000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-9830000
usph Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRate
0.2625
CY2020Q2 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
878000
CY2019Q2 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-1356000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
1437000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-2580000
CY2020Q2 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
12698000
CY2019Q2 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
10807000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
15284000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
15813000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.99
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.24
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12843000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12767000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12820000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12738000
CY2019Q4 us-gaap Goodwill
Goodwill
317676000
CY2018Q4 us-gaap Goodwill
Goodwill
293525000
CY2019Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2277000
CY2019 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
146000
CY2020Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1987000
CY2019Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
116000
CY2020Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
4637000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0
CY2019 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
31330000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16809000
us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
0
CY2019 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
7325000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19340000
CY2020Q2 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
6871000
CY2019Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
4303000
CY2020Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2180000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
13845000
CY2020Q2 us-gaap Goodwill
Goodwill
330894000
CY2019Q4 us-gaap Goodwill
Goodwill
317676000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1900000
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
54895000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
52588000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
923000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
750000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1713000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1452000
CY2020Q2 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
12861000
CY2019Q4 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
0
CY2020Q2 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
2155000
CY2019Q4 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
0
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3825000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4819000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51325000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30855000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
43000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
7815000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
7708000
us-gaap Operating Lease Cost
OperatingLeaseCost
15627000
us-gaap Operating Lease Cost
OperatingLeaseCost
15295000
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
215000
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
297000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
509000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
668000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1514000
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1547000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
98514000
us-gaap Variable Lease Cost
VariableLeaseCost
3046000
us-gaap Variable Lease Cost
VariableLeaseCost
3128000
CY2020Q2 us-gaap Lease Cost
LeaseCost
9544000
CY2019Q2 us-gaap Lease Cost
LeaseCost
9552000
us-gaap Lease Cost
LeaseCost
19182000
us-gaap Lease Cost
LeaseCost
19091000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
6555000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
7686000
us-gaap Operating Lease Payments
OperatingLeasePayments
14345000
us-gaap Operating Lease Payments
OperatingLeasePayments
15392000
CY2020Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7535000
CY2019Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8629000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19075000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
15568000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
26363000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
20565000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
14968000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9439000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10288000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
97191000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6359000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
90832000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M15D
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M15D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.032
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.032
CY2020Q2 us-gaap Revenues
Revenues
83857000
CY2019Q2 us-gaap Revenues
Revenues
126373000
us-gaap Revenues
Revenues
196574000
us-gaap Revenues
Revenues
242604000
CY2020Q2 us-gaap Gross Profit
GrossProfit
19284000
CY2019Q2 us-gaap Gross Profit
GrossProfit
31425000
us-gaap Gross Profit
GrossProfit
34975000
us-gaap Gross Profit
GrossProfit
58143000
CY2020Q2 us-gaap Assets
Assets
585018000
CY2019Q2 us-gaap Assets
Assets
560845000
CY2008Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
2250000
CY2009Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1200000
CY2009Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
859499
usph Additional Estimated Repurchase Of Common Stock
AdditionalEstimatedRepurchaseOfCommonStock
185139
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
81.02
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0

Files In Submission

Name View Source Status
0001140361-20-017773-index-headers.html Edgar Link pending
0001140361-20-017773-index.html Edgar Link pending
0001140361-20-017773.txt Edgar Link pending
0001140361-20-017773-xbrl.zip Edgar Link pending
brhc10014105_10q.htm Edgar Link pending
brhc10014105_10q_htm.xml Edgar Link completed
brhc10014105_ex31-1.htm Edgar Link pending
brhc10014105_ex31-2.htm Edgar Link pending
brhc10014105_ex31-3.htm Edgar Link pending
brhc10014105_ex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20200630.xsd Edgar Link pending
usph-20200630_cal.xml Edgar Link unprocessable
usph-20200630_def.xml Edgar Link unprocessable
usph-20200630_lab.xml Edgar Link unprocessable
usph-20200630_pre.xml Edgar Link unprocessable